thalassemia refers specifically to the abnormal or absent manufacturing of alpha-globin chains. These are associated with more than 15 different genetic mutations. The severity of the clinical ...

YolTech Therapeutics, a clinical-stage gene editing company dedicated to delivering lifelong cures, announced the initiation of a clinical trial for YOLT-204, an investigational therapy for the ...

YolTech Therapeutics CEO and founder Dr Yuxuan Wu said: "The initiation of the clinical trial for YOLT-204 represents a ...

Known as Zynteglo in Europe where it is approved to treat the rare blood disorder beta-thalassemia ... triggering a mutation or disrupting a mechanism that guards against a cell becoming cancerous.

On January 21st, the Thalassemia International Federation (TIF) and BGI Genomics jointly hosted an educational webinar focused on thalassemia prevention in high-prevalence regions. Experts emphasized ...

It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of ... cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial.

You will be able to get a quick price and instant permission to reuse the content in many different ways. Beta-thalassemia is a heterogenous autosomal recessive blood disorders that arise due to ...